Talkdesk Enters Next Decade Fueled by Innovation, Expanded International Presence, New Brand
27.4.2021 18:30:00 EEST | Business Wire | Press release
Talkdesk®, Inc., the global customer experience leader for customer-obsessed companies, today embarked on the next phase of growth after two years of significant momentum in executing toward its bold vision to provide a better way for organizations to unlock the promise and potential of great customer service. To mark this new stage in its corporate maturation, Talkdesk unveiled a new logo and tagline – Experience. A better way. – that reflects the company’s commitment to being at the forefront of customer experience (CX) innovation and its focus on empowering customers to build brand trust and loyalty through customized, personal interactions.
Talkdesk’s reimagined logo reflects its commitment to helping companies connect every engagement moment into customer journeys that are personalized, productive and profitable. The bold new corporate identity comprises a fresh purple color palette and updated brand elements, featuring inclusive and diverse visual representations and illustrations that reflect the importance of human connection. The company also relaunched its website in five new languages – Brazilian Portuguese, French, German, Portuguese and Spanish, and unveiled a powerful new international advertising campaign.
“Today is about retelling the Talkdesk story in a way that pays tribute to our legacy, embraces our commitment to diversity and giving back, and deeply connects our path forward to the thousands of Talkdesk customers and employees who made what is yet to come possible,” said Kathie Johnson, chief marketing officer, Talkdesk. “Every element of who we are represents the importance of the connection we help companies make with their customers, because every moment matters.”
Talkdesk today also introduced availability of two additions to Talkdesk CX Cloud™ designed to propel the company into its new wave of growth: Talkdesk Workspace, a customizable user interface, and Talkdesk Builder, a set of tools for unlimited and accelerated contact center customization across workspaces, routing, reporting and integrations. Since its inception, rapid innovation has been a Talkdesk hallmark – one applauded by both customers and industry leaders, and valued by enterprise customers worldwide.
“Ten years ago, Talkdesk founder Tiago Paiva saw how Salesforce had re-invented the CRM world and realized a similar revolution was imminent for the call center,” said Sheila McGee-Smith, founder and principal analyst, McGee-Smith Analytics, LLC. “Talkdesk has been a significant part of the industry-wide contact center transformation, helping to move the industry toward a true elastic cloud, with all the innovation power that brings for not just customers but the entire customer experience ecosystem.”
Over the past 24 months, Talkdesk achieved several significant milestones, including:
- An international expansion that extended the company’s footprint not only within Portugal, the United Kingdom and the United States, but also into Australia, Brazil, France, Germany, Ireland, Italy, the Netherlands, Southeast Asia and Spain
- A proven executive leadership team – which is 45% female – with experience at some of the technology industry’s leading companies, including AT&T, Cloudera, Oracle, Salesforce and SAP
- Bringing to market 20 innovations in the first 20 weeks of 2020, including solutions designed to help its customers through the pandemic
- Expansion and strengthening of its partner ecosystem of cloud distributors, resellers, marketplace and strategic alliance partners
- Launching industry specific solutions to help address the unique customer service challenges of financial services and insurance, healthcare and life sciences, retail and e-commerce, and travel and hospitality companies
- Raising Series C funding of $143 million, bringing the company’s valuation to more than $3 billion
- Positioned as a leader in the 2020 Gartner Cloud Contact Center as a Service (CCaaS) Magic Quadrant
- Positioned as a leader in the 2020 Forrester Wave for CCaaS
“Today marks an inflection point in Talkdesk history. Talkdesk was founded on the principle that there had to be a better way for companies to deliver exceptional customer service. We now have customers in every major region of the world who have transformed their end-customers’ experience into an immersive, personalized and profitable journey,” said Tiago Paiva, Talkdesk founder and chief executive officer. “Our cloud-native platform was one of many industry-firsts Talkdesk introduced to the contact center marketplace over its first decade, and our talented
development team is hard at work on the products that will define our next 10 years of audacious innovation.”
Additional Resources
- Read Kathie Johnson’s perspective on leading Talkdesk through transformation growth as the company’s first chief marketing officer
- Read the press release introducing Talkdesk Workspace, a customizable interface designed to enable a better way to deliver superior customer experiences in contact centers
- Learn more about the new Talkdesk brand
Social Networks
- Web: https://www.talkdesk.com
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global customer experience leader for customer-obsessed companies. Our contact center solution provides a better way for businesses and customers to engage with one another. Our speed of innovation and global footprint reflect our commitment to ensure businesses everywhere can deliver better customer experiences through any channel, resulting in higher customer satisfaction, cost savings and profitability. Talkdesk CX CloudTM is an end-to-end customer experience solution that combines enterprise scale with consumer simplicity. Over 1,800 innovative companies around the world, including IBM, Acxiom, Trivago, and Fujitsu partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks ™ or registered ® trademarks of their respective holders. Use of the does not imply any affiliation or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005860/en/
Contact information
Media Contacts:
Americas
Camille Beasley
camille.beasley@talkdesk.com
(972) 896-1936
EMEA
Douglas Keighley
douglas.keighley@talkdesk.com
+44 7830144613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
